Harga 2 Obat Rekomendasi Terbaru WHO untuk Pasien Covid-19, Tembus Jutaan Rupiah

Any Hidayati

Editor:

  • WHO merekomendasikan Actemra dan Kevzara untuk obat Covid-19.
  • Actemra dibandrol dengan harga Rp1.162.200 dan Rp5.710.600 tergantung dosis.
  • Kevzara belum resmi masuk Indonesia tapi di AS dipatok dengan harga sekitar Rp55 juta untuk dosis 150mg/1,14ml.

SKOR.id - Selasa (6/7/2021), Badan Kesehatan Dunia (WHO) merekomendasikan dua jenis obat radang sendi untuk pengobatan Covid-19.

Dilansir dari Reuters.com, obat yang dimaksud oleh WHO tersebut adalah Actemra dari Roche dan Kevzara dari Sanofi.

Kedua obat tersebut telah diuji WHO kepada 10.930 pasien Covid-19 kategori berat dan kritis yang mana pasien yang mendapat suntikan salah satu obat tersebut memiliki progres positif ketimbang yang hanya mendapat perawatan biasa.

Sebanyak 6.449 orang menggunakan salah satu obat radang sendi tersebut memiliki kemungkinan hidup lebih besar dari 4.481 orang lainnya hanya mendapat perawatan biasa selama 28 hari pengujian tersebut.

Dilansir dari Kompas.com, obat jenis Acterma dapat mengatasi badai sitokin atau respon berlebihan tubuh terhadap infeksi ketika terpapar Covid-19.

Sehingga kerusakan organ tubuh akibat badai sitokin saat terpapar Covid-19 dapat ditekan karena menurunkan beberapa penanda inflamasi atau peradangan.

Meskipun telah teruji klinis, Actemra dan Kevzara adalah obat radang sendi yang tergolong obat keras.

Sehingga obat tersebut harus mendapat pengawasan ketat dari dokter atau tenaga kesehatan selama proses pemulihan.

Badan pengawas obat dan makanan Amerika Serikat telah memberikan izin edar untuk dua jenis obat tersebut sejak pekan lalu.

Di Indonesia, baru Actemra yang telah resmi beredar di pasaran dan mendapat izin edar dari Badan Pengawas Obat dan Makanan (BPOM).

Actemra atau Tocilizumab dosis 400mg/20ml dijual dengan harga Rp5.710.600. Sedangkan, dosis 80mg/4ml dibandrol dengan harga Rp1.162.200.

Kevzara di Amerika Serikat dipatok dengan harga 3.827 dolar AS atau setara Rp55 juta untuk dosis 150mg/1,14ml.

Walaupun telah direkomendasikan oleh WHO, dua obat radang sendi tersebut mempunyai beberapa efek samping untuk pemakainya.

Dilansir dari KATADATA Indonesia, kedua obat tersebut memiliki efek samping antara lain, infeksi pernapasan, sakit kepala, tekanan darah tinggi, peningkatan enzim hati, dan alergi.

Ikuti juga InstagramFacebookYouTube, dan Twitter dari Skor Indonesia.

Berita Covid-19 Lainnya:

Mengenal Perbedaan Sinovac dan AstraZeneca, 2 Vaksin yang Dipakai di Indonesia

Catat, Hal yang Perlu Diperhatikan Sebelum dan Setelah Vaksinasi Covid-19

Source: KompasReutersKata Data

RELATED STORIES

5 Bintang NBA yang Gagal Lolos ke Olimpiade Tokyo, 2 MVP Jadi Korban

5 Bintang NBA yang Gagal Lolos ke Olimpiade Tokyo, 2 MVP Jadi Korban

Ada beberapa pemain asing NBA yang berstatus bintang namun absen di Olimpiade 2020 Tokyo karena negaranya tak lolos

3 Rekomendasi Olahraga saat Isolasi Mandiri dengan Gejala Ringan Covid-19

Demi menjaga diri dan lingkungan sekitar, masyarakat yang mengalami gejala ringan-sedang Covid-19 disarankan untuk melakukan isolasi mandiri.

Skor co creators network
RIGHT_ARROW
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
RIGHT_ARROW

THE LATEST

Alumni Liga TopSkor TC Timnas U-23 Indonesia.

Liga TopSkor

Belasan Alumni Liga TopSkor Ikuti TC Timnas U-23 Indonesia

Total 11 Alumni Liga TopSkor akan menjadi bagian dalam pemusatan latihan Timnas U-23 Indonesia untuk persiapan berlaga di Piala AFF U-23 2025.

Nizar Galang | 17 Jun, 07:40

Timnas U-23 Indonesia.

Timnas Indonesia

Dua Pemain Persib Batal Dipanggil Timnas U-23 Indonesia

Dua pemain Persib Bandung batal dipanggil mengikuti pemusatan latihan Timnas U-23 Indonesia. Siapa saja?

Rais Adnan | 17 Jun, 07:22

PSPS Pekanbaru - Hendy AS - Skor.id

Liga 2

PSPS Resmi Datangkan Kurniawan Dwi Yulianto, Tim Pelatih Komplet untuk Liga 2 2025-2026

PSPS Pekanbaru resmi merampungkan tim kepelatihan untuk musim baru usai gagal promosi pada Liga 2 2024-2025.

Taufani Rahmanda | 17 Jun, 05:36

cover bursa transfer Liga 1.

Liga 1

Update Bursa Transfer Liga 1 Menuju Musim 2025-2026

Aktivitas keluar-masuk pemain dan jajaran pelatih tim 18 klub Liga 1 2025-2026 pada awal musim, yang diperbaharui berkala.

Taufani Rahmanda | 17 Jun, 04:52

Kompetisi futsal putri kasta tertinggi di Indonesia untuk musim terbaru, Women Pro Futsal League 2024-2025. (Deni Sulaeman/Skor.id)

Futsal

Women Pro Futsal League 2024-2025: Jadwal, Hasil dan Klasemen Lengkap

Jadwal, hasil, dan klasemen Women Pro Futsal League 2024-2025 yang terus diperbaharui seiring berjalannya kompetisi.

Taufani Rahmanda | 17 Jun, 04:48

Logo baru kompetisi futsal kasta tertinggi di Indonesia, Pro Futsal League 2024-2025. (Rahmat Ari Hidayat/Skor.id)

Futsal

Pro Futsal League 2024-2025: Jadwal, Hasil, dan Klasemen Lengkap

Jadwal, hasil, dan klasemen Pro Futsal League 2023-2024 terus diperbaharui seiring berjalannya kompetisi.

Taufani Rahmanda | 17 Jun, 04:45

Team Vitality. (Jovi Arnanda/Skor.id)

Esports

Pemain Team Vitality Sebut Indonesia Kekurangan Kompetisi Ladies

Team Vitality sendiri baru menjalani satu kompetisi ladies saja di tahun ini yakni Battle of Gamehers.

Gangga Basudewa | 17 Jun, 04:39

PMSL SEA Summer 2025. (PUBG Mobile)

Esports

Daftar 16 Tim di Grand Final PMSL SEA Summer 2025

Dari 16 tim, tujuh (7) tim merupakan perwakilan dari Indonesia di PMSL SEA Spring 2025.

Gangga Basudewa | 17 Jun, 04:39

 Enzo Fernandez, pesepak bola Chelsea. (Dede Mauladi/Skor.id)

World

Hasil Piala Dunia Antarklub: Chelsea Menang, Boca Imbang

Chelsea menang dan Boca Juniors imbang lawan Benfica menghiasi hasil Piala Dunia Antarklub 2025 hari ini.

Thoriq Az Zuhri | 17 Jun, 02:58

Trofi baru Piala Dunia Antarklub FIFA didesain inovatif dengan sarat makna. (Dede Sopatal Mauladi/Skor.id)

World

Piala Dunia Antarklub 2025: Jadwal, Hasil, dan Klasemen Lengkap

Jadwal, hasil, dan klasemen Piala Dunia Antarklub 2025, yang akan diperbarui seiring berjalannya kompetisi.

Pradipta Indra Kumara | 17 Jun, 02:58

Load More Articles